ConductScience.org, home

Paper38108398

Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation.

Elkrief A and 28 others. Cancer Immunol Res, 2024. Cited by 39 papers, by iCite.

Cite this record

ConductScience Library. Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation. Papers, record 38108398. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38108398

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation.
PubMed
Journal
Cancer Immunol Res
PubMed
Year
2024
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
39
iCite
Relative citation ratio, by iCite
4.22, provisional
iCite
Revised in PubMed
2024-09-05
PubMed

Authors29

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Gastrointestinal MicrobiomeMajor topic
ColitisMajor topic
Biological ProductsMajor topic
Humans
Fecal Microbiota Transplantation
Prospective Studies
Dysbiosis
Treatment Outcome

Source PubMed

Download CSV of topics

Grants9

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P01 CA023766NCI NIH HHSUnited StatesP01CA023766PubMed and NIHNIH RePORTER
R01 CA228308NCI NIH HHSUnited StatesR01CA228308PubMed and NIHNIH RePORTER
R01 HL147584NHLBI NIH HHSUnited StatesR01HL147584PubMed and NIHNIH RePORTER
P50 CA254838NCI NIH HHSUnited StatesP50CA254838PubMed and NIHNIH RePORTER
R01 CA228358NCI NIH HHSUnited StatesR01CA228358PubMed and NIHNIH RePORTER
K08 HL143189NHLBI NIH HHSUnited StatesK08HL143189PubMed and NIHNIH RePORTER
R01 HL123340NHLBI NIH HHSUnited StatesR01HL123340PubMed and NIHNIH RePORTER
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIHNIH RePORTER
P01 AG052359NIA NIH HHSUnited StatesP01AG052359PubMed and NIHNIH RePORTER

Download CSV of grants

References56

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131488205Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis.J Immunother Cancer2019https://conductscience.org/library/papers/31488205PubMed
235082367Immune-checkpoint inhibitors: long-term implications of toxicity.Nat Rev Clin Oncol2022https://conductscience.org/library/papers/35082367PubMed
326282644
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
J Clin Oncol2015https://conductscience.org/library/papers/26282644PubMed
428915085Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.J Clin Oncol2017https://conductscience.org/library/papers/28915085PubMed
529442540Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol2018https://conductscience.org/library/papers/29442540PubMed
629255284Enterotypes in the landscape of gut microbial community composition.Nat Microbiol2018https://conductscience.org/library/papers/29255284PubMed
729975414High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.Cancer2018https://conductscience.org/library/papers/29975414PubMed
830420754Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.Nat Med2018https://conductscience.org/library/papers/30420754PubMed
929097493Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.Science2018https://conductscience.org/library/papers/29097493PubMed
1031328416Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.Thorac Cancer2019https://conductscience.org/library/papers/31328416PubMed
1132603654Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy.Cell2020https://conductscience.org/library/papers/32603654PubMed
1227126039Population-level analysis of gut microbiome variation.Science2016https://conductscience.org/library/papers/27126039PubMed
1332847937The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer.Cancer Immunol Res2020https://conductscience.org/library/papers/32847937PubMed
1433675691Understanding and treating the inflammatory adverse events of cancer immunotherapy.Cell2021https://conductscience.org/library/papers/33675691PubMed
1533246931Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.ESMO Open2020https://conductscience.org/library/papers/33246931PubMed
1634239137Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.Nat Med2021https://conductscience.org/library/papers/34239137PubMed
1729617710Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.Ann Oncol2018https://conductscience.org/library/papers/29617710PubMed
1835194180Regulation of tissue-resident memory T cells by the Microbiota.Mucosal Immunol2022https://conductscience.org/library/papers/35194180PubMed
1933171025The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients.Cancer Res Treat2021https://conductscience.org/library/papers/33171025PubMed
2032294209Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy.J Natl Cancer Inst2021https://conductscience.org/library/papers/32294209PubMed

See all 56 referencesDownload CSV of references

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 39 citations.

PMIDTitleJournalYearIn PapersSource
42913630Lifestyle-induced regulatory T cell fragility primes adverse events after immune checkpoint blockade.Cell2026https://conductscience.org/library/papers/42913630PubMed
42903966Interactions between microbiota and innate immunity in tumor microenvironment: Novel insights into cancer progression and immunotherapy.Hlife2025https://conductscience.org/library/papers/42903966PubMed
42735684First-line fecal microbiota transplantation for the management of immune checkpoint inhibitor-mediated diarrhea and colitis.Cell Rep Med2026https://conductscience.org/library/papers/42735684PubMed
42721039B cell-guided inflammatory cascade perpetuates ICI-mediated colitis.Cell Rep2026https://conductscience.org/library/papers/42721039PubMed
42602359Application and prospects of fecal microbiota transplantation in cancer therapy.Front Cell Infect Microbiol2026https://conductscience.org/library/papers/42602359PubMed
42564206Integrated cellular, proteomic and metabolomic profiling of immune-related adverse events in non-small cell lung cancer.Front Immunol2026https://conductscience.org/library/papers/42564206PubMed
42493518Microbial engraftment and immune regulation during fecal microbiota transplantation and immune checkpoint inhibitor therapy.Nat Commun2026https://conductscience.org/library/papers/42493518PubMed
42233032Research landscape, thematic evolution, and translational insights of immune checkpoint inhibitor-induced colitis: a bibliometric analysis (2006-2025).Front Immunol2026https://conductscience.org/library/papers/42233032PubMed
42204645Decoding the microbiome-immune crosstalk in cancer: from mechanisms to therapeutic translation.Biomark Res2026https://conductscience.org/library/papers/42204645PubMed
42083059Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer.Microbiome2026https://conductscience.org/library/papers/42083059PubMed
41992000Microbiota and immune-related adverse events in cancer immunotherapy.Nat Rev Cancer2026https://conductscience.org/library/papers/41992000PubMed
41898402Across the Social Network of the Gut: Bacterial, Fungal, and Viral Determinants of Checkpoint Inhibitor Efficacy and Toxicity.Int J Mol Sci2026https://conductscience.org/library/papers/41898402PubMed
41644742Toward Microbiome-Informed Melanoma Care: The Gut Microbiota in Melanoma Evolution, Immunotherapy Response and Immune-Related Toxicity.Curr Oncol Rep2026https://conductscience.org/library/papers/41644742PubMed
41606121Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.Nat Med2026https://conductscience.org/library/papers/41606121PubMed
41606120Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial.Nat Med2026https://conductscience.org/library/papers/41606120PubMed
41545303Steroid-sparing strategies for managing immune-related adverse events.J Immunother Cancer2026https://conductscience.org/library/papers/41545303PubMed
41535719Gut dysbiosis in oncology: a risk factor for immunoresistance.Cell Res2026https://conductscience.org/library/papers/41535719PubMed
41374078Inflammatory Bowel Disease, Gastrointestinal Graft-Versus-Host Disease and Immune Checkpoint Inhibitors Induced Colitis: Similar Diseases to Treat with Fecal Microbiota Transplantation.Nutrients2025https://conductscience.org/library/papers/41374078PubMed
41349548Harnessing the Microbiome in Cancer Immunotherapy: Regulation, Prediction, and Therapeutic Targeting.Annu Rev Immunol2026https://conductscience.org/library/papers/41349548PubMed
41304963Fecal Microbiota Transplantation in Refractory Immune-Mediated Colitis: Case Series and Review of the Literature.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/41304963PubMed

See all 30 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38108398

GET https://conductscience.org/api/papers/v1/38108398/authors?page=2